Actuate Therapeutics (ACTU) Convertible Debt (2024)
Actuate Therapeutics (ACTU) posted quarterly Convertible Debt of $6.9 million for Q2 2024.
Actuate Therapeutics (ACTU) Convertible Debt (2024) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Convertible Debt for 1 consecutive years, with $6.9 million the latest figure, recorded in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Actuate Therapeutics | 29.84 Mn | 29.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 6.90 Mn |